Miscarriage

Researchers are conducting a nationwide observational study in China to create a detailed group of patients diagnosed with hydatidiform mole, a type of molar pregnancy. The study's main focus is to understand how often these moles become cancerous and to explore the mechanisms behind this transformation. The goal is to improve and spread precise diagnosis and treatment methods for this condition across the country. This study involves closely monitoring patients without providing any additional treatment, supporting the development of evidence-based care strategies for molar pregnancy. Patients will have their beta-hCG hormone levels checked regularly after uterine evacuation to watch for signs of malignant changes. Those with partial hydatidiform mole can stop follow-up once hormone levels normalize, while patients with complete hydatidiform mole will be monitored monthly for six months due to a higher risk of progression. Participants will undergo regular clinical and pathological evaluations, including hormone monitoring every 1-2 weeks post-surgery. Researchers will also assess fertility outcomes at one and two years and measure psychological well-being using anxiety, depression, and reproductive concern scales three months after uterine evacuation. Follow-up will continue for at least six months to track any malignant changes, with the total study duration extending up to several years depending on individual patient progress.

Researchers are exploring the best treatment approach for retained products of pregnancy, a condition where tissue remains in the uterus after pregnancy. This study aims to see if managing the condition with medication and waiting for the right time to perform surgery reduces the risk of intrauterine adhesions, which can affect fertility. The study is observational and compares this drug-assisted expectant management to immediate surgical treatment. Participants will be assigned to one of two groups: one group will have immediate hysteroscopic removal of pregnancy tissue under anesthesia, while the other group will receive medication and careful monitoring until surgery is needed or the condition resolves. The medication includes hormone therapy and herbal treatments, with regular ultrasound and blood tests to guide timing for surgery if necessary. During the study, participants will be closely monitored with ultrasound scans and blood tests to assess healing and complications. Researchers will track outcomes such as the presence of uterine adhesions three months after treatment, need for additional surgery, pregnancy rates within one year, bleeding, infections, blood loss during surgery, and uterine lining thickness. Participants will be followed up to one year after treatment to observe these outcomes and overall reproductive health.

Researchers are investigating the effects of conservative treatment on people with retained products of conception (RPOC) and enhanced myometrial vascularity (EMV) following miscarriage or delivery. The study aims to determine whether natural resolution of RPOC can be achieved by combining it with EMV through conservative methods. This observational study is led by Fu Xing Hospital, Capital Medical University, and focuses on evaluating therapeutic outcomes after two menstrual cycles. Participants will receive conservative treatments such as mifepristone, GnRH-a, or expectant management after being diagnosed with RPOC and EMV. The main treatment period spans two menstrual cycles, after which therapeutic effects will be assessed. No additional interventions or comparison groups are mentioned, as this is an observational study monitoring natural and treatment-influenced resolution. During the study, participants will undergo transvaginal ultrasound at the end of the second menstrual cycle to check for resolution of RPOC. Researchers will also measure the disappearance rate of EMV immediately after completing conservative treatment. The study will track participants' response to treatment and monitor their health status, with a focus on treatment efficacy and safety throughout the observation period ending in late 2026.

Researchers are studying different treatments for early missed abortion, a condition where the pregnancy fails but is not immediately expelled. This study aims to compare the effectiveness of surgical and medical approaches, including how different doses of estrogen might improve outcomes and reduce complications. It includes both a retrospective analysis and a prospective study to find the best treatment method for early missed abortion. The trial involves several treatment groups: one receiving surgery without estrogen, another undergoing surgery with estrogen before the procedure, and two medical treatment groups using mifepristone combined with misoprostol, with or without added estrogen. Surgery is performed under ultrasound guidance or laparoscopically with general anesthesia, while medication is given in specific doses and repeated if needed. Estrogen is administered orally for several days in the estrogen groups. Participants will be closely monitored through clinical exams, ultrasound, and laboratory tests. The main outcomes measured include the rate of complete abortion within 14 days, presence of intrauterine adhesions three months after treatment, and reproductive outcomes up to one year after treatment. Other evaluations include blood loss during surgery, time to expel pregnancy tissue with medication, adverse reactions, menstrual changes, and residual tissue after treatment. Follow-up visits occur at defined intervals to assess these outcomes over time.

Researchers are conducting a prospective longitudinal study in Lusaka, Zambia, to better understand the pregnancy rates and outcomes among women of reproductive age. The study aims to explore the health and well-being of women before, during, and after pregnancy, as well as the factors that may affect adverse outcomes during these reproductive periods. This information is intended to improve care for mothers and their children in the future. Women aged 15 to 49 years who live in the study area will be enrolled and followed for up to three years. Participants will be visited every three months, during which their medical records will be reviewed, a brief physical exam and urine pregnancy test will be conducted, and they will answer survey questions. Women will also collect vaginal swabs themselves for future testing. Infants born to participating women during the study will also be included. During the study, researchers will collect data on pregnancy rates, term live births, and infant mortality, measured over the entire enrollment period up to 36 months. The study involves regular health assessments and surveys to monitor participants' well-being. Safety and data interpretation will be closely monitored, considering any social or medical factors that could affect participation. Total participation may last up to three years, with quarterly visits to support continuous observation and data collection.

Researchers are studying the effects of early use of low-dose aspirin in pregnant women who have risk factors for preeclampsia or pregnancy loss. The study aims to find out if starting aspirin at a specific dose and time during pregnancy can lower the chances of developing preeclampsia or experiencing pregnancy loss compared to the usual recommendations. This is a Phase 3 clinical trial led by the University of Pennsylvania. Participants will be randomly assigned to one of two groups. One group will take two 81mg aspirin tablets daily from the start of the trial until delivery. The other group will take placebo pills until 12 weeks of pregnancy and then switch to one placebo and one 81mg aspirin tablet daily until delivery. The treatment starts no later than 6 weeks and 6 days of pregnancy and continues through delivery. During the study, participants will be monitored from enrollment through delivery, with researchers tracking outcomes such as preeclampsia, pregnancy loss, and other pregnancy complications. The main results measured include the occurrence of preeclampsia from 20 weeks of pregnancy to delivery and pregnancy loss up to 24 weeks gestation. Additional outcomes involve various pregnancy-related conditions and birth outcomes. The study includes safety monitoring and lasts through the entire pregnancy period, with careful follow-up until delivery.

Researchers are investigating the relationship between low plasma mannose binding lectin (p-MBL) levels and unexplained reproductive failures, including recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF). The study focuses on patients with reproductive difficulties after assisted reproductive technologies (ART) such as IVF, ICSI, and frozen embryo transfer (FET), as well as after spontaneous conception. The goal is to better understand if low p-MBL levels contribute broadly to reproductive challenges in early pregnancy stages. The study observes three groups of women: those with three consecutive pregnancy losses after spontaneous conception, three losses after ART treatments, and those who experienced three failed embryo transfers with good-quality embryos but no clinical pregnancy. Blood samples are collected from participants when they are not pregnant or before 9 weeks gestation to measure p-MBL levels, categorizing them as low, very low, or high. Participants undergo assessments including blood sampling to measure p-MBL levels, which are the primary outcomes of interest. Secondary measures include calculating the odds ratios for low p-MBL levels among these groups. The study excludes women outside the age range or with certain uterine or chromosomal conditions. The research aims to clarify p-MBL's role in early pregnancy failure mechanisms, helping future evaluation of reproductive failure cases.

Pregnancy is a crucial time to assess and manage cardiovascular health risks for both mothers and their children. Researchers are studying the use of the American Heart Association's "Life's Essential 8" as a new way to evaluate cardiovascular health in pregnant women. The goal is to better understand how this tool can be applied and to develop appropriate cardiovascular health standards during pregnancy. The study involves observing pregnant women aged 20 to 49 who conceived naturally and are carrying a single baby. Participants will complete questionnaires, undergo clinical follow-ups, and provide specimens for analysis. The research focuses on monitoring cardiovascular health throughout pregnancy to explore its impact on pregnancy outcomes. During the study, researchers will track maternal and newborn health outcomes up to 42 weeks of gestation. Participants will be involved in routine prenatal checkups and data collection to support the study's assessments. This observational study helps gather important information on cardiovascular health during pregnancy without altering the standard care process.

This research aims to explore the effectiveness and duration of autologous decidual-like natural killer (NK) cells therapy in improving uterine NK cell dysfunction in women with infertility or a history of adverse pregnancy outcomes. It focuses on patients with abnormal uterine NK cell function and fertility needs, seeking to understand how this therapy might help with such reproductive challenges. The treatment involves collecting peripheral blood from each patient to isolate and culture autologous decidual-like NK cells in the laboratory. These cells are then infused into the patient's uterus through intrauterine perfusion. If the uterine NK cell function improves within six months after the first treatment, the patient can attempt pregnancy, with follow-up of pregnancy outcomes. If there is no improvement, a second infusion of the same therapy may be given, with up to two treatments total. Participants will undergo continuous menstrual blood analysis for six months to monitor uterine NK cell function after treatment. Researchers will also track pregnancy outcomes, including clinical pregnancy, ongoing pregnancy, live birth, preeclampsia, and fetal growth restriction for up to one year after therapy completion. The study includes safety and effectiveness assessments during this follow-up period, with a total participation duration extending to about one year after treatment.

Researchers are studying how biochemical factors and ultrasound measurements can predict pregnancy outcomes in women experiencing threatened abortion during the first trimester. This prospective cohort study focuses on women aged 19 to 39 years with a single pregnancy between 6 and 11 weeks gestation, aiming to understand ongoing pregnancy rates at 12 weeks of gestational age. Participants undergo multiple ultrasound scans using 2D and 3D techniques. Initial assessments include crown-rump length, yolk sac diameter, gestational sac diameter, and embryonic heart rate measured by 2D ultrasound, alongside yolk sac volume measured by 3D ultrasound using the VOCAL method. These scans are performed at the start, then again after 1 to 2 weeks, and finally at the end of the 12th week of gestation. Throughout the study, women will be monitored with these ultrasound evaluations to track pregnancy progression. Researchers will analyze these measurements to assess their ability to predict pregnancy continuation. The study involves ongoing pregnancy rate assessment at 12 weeks and includes detailed imaging and biometric data collection at specified intervals.